Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1997;96:2823-2829

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sim, I.
Right arrow Articles by Hlatky, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sim, I.
Right arrow Articles by Hlatky, M. A.

(Circulation. 1997;96:2823-2829.)
© 1997 American Heart Association, Inc.


Articles

Quantitative Overview of Randomized Trials of Amiodarone to Prevent Sudden Cardiac Death

Ida Sim, MD; Kathryn M. McDonald, MM; Philip W. Lavori, PhD; Catherine M. Norbutas, BS; ; Mark A. Hlatky, MD

From the Department of Health Research and Policy and the Department of Medicine, Stanford (Calif) University School of Medicine, and the VA Informatics Program and the VA Cooperative Studies Program, Palo Alto (Calif) VA Health Care System.

Correspondence to Mark A. Hlatky, MD, Stanford University School of Medicine, HRP Redwood Bldg, Room 150, Stanford, CA 94305-5092. E-mail mr.mah{at}forsythe.stanford.edu

Background Some randomized clinical trials of amiodarone therapy to prevent sudden cardiac death have had positive results and others have had negative results, but all were relatively small. This meta-analysis aimed to pool all trials to assess the effect of amiodarone on mortality and the impact of differences in patient population and study design on trial outcomes.

Methods and Results Fifteen randomized trials were identified, and outcome measures were combined by use of a random effects model. The effect of patient population and study design on total mortality was assessed by use of a hierarchical Bayes model. Amiodarone reduced total mortality by 19% (confidence limits, 6% to 31%; P<.01), with somewhat greater reductions in cardiac mortality (23%, P<.001) and sudden death (30%, P<.001). Mortality reductions were similar in trials enrolling patients after myocardial infarction (21%), with left ventricular dysfunction (22%), and after cardiac arrest (25%). There was a trend toward greater risk reduction in trials requiring evidence of ventricular ectopy (25%) than in the remaining trials (10%). The trials using placebo controls had considerably less risk reduction (10%) than trials with active controls (27%) or usual care controls (42%, posterior odds <0.02).

Conclusions Amiodarone reduced total mortality by 10% to 19% in patients at risk of sudden cardiac death. Amiodarone reduced risk similarly in patients after myocardial infarction, with heart failure, or with clinically evident arrhythmia. The apparent inconsistencies among results of randomized trials appear to be due to small sample sizes and the type of control group used, not the type of patient enrolled.


Key Words: meta-analysis • antiarrhythmia agents • death, sudden • prevention • amiodarone




This article has been cited by other articles:


Home page
Eur Heart JHome page
J. P. Piccini, J. S. Berger, and C. M. O'Connor
Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials
Eur. Heart J., May 2, 2009; 30(10): 1245 - 1253.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al.
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death)
J. Am. Coll. Cardiol., September 5, 2006; 48(5): e247 - e346.
[Full Text] [PDF]


Home page
EuropaceHome page
Writing Committee Members, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al.
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Europace, September 1, 2006; 8(9): 746 - 837.
[Full Text] [PDF]


Home page
PediatricsHome page
The International Liaison Committee on Resuscitati
The International Liaison Committee on Resuscitation (ILCOR) Consensus on Science With Treatment Recommendations for Pediatric and Neonatal Patients: Pediatric Basic and Advanced Life Support
Pediatrics, May 1, 2006; 117(5): e955 - e977.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
M C S Hall and D M Todd
Modern management of arrhythmias
Postgrad. Med. J., February 1, 2006; 82(964): 117 - 125.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
Part 6: Pediatric Basic and Advanced Life Support
Circulation, November 29, 2005; 112(22_suppl): III-73 - III-90.
[Full Text] [PDF]


Home page
EuropaceHome page
K. A. Gatzoulis, G. K. Andrikopoulos, T. Apostolopoulos, E. Sotiropoulos, G. Zervopoulos, J. Antoniou, S. Brili, and C. I. Stefanadis
Electrical storm is an independent predictor of adverse long-term outcome in the era of implantable defibrillator therapy
Europace, January 1, 2005; 7(2): 184 - 192.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
S. Z. Pantilat and A. E. Steimle
Palliative Care for Patients With Heart Failure
JAMA, May 26, 2004; 291(20): 2476 - 2482.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. R. Reynolds and M. E. Josephson
MADIT II (Second Multicenter Automated Defibrillator Implantation Trial) Debate: Risk Stratification, Costs, and Public Policy
Circulation, October 14, 2003; 108(15): 1779 - 1783.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. A. Strickberger, J. D. Hummel, T. G. Bartlett, H. I. Frumin, C. D. Schuger, S. L. Beau, C. Bitar, F. Morady, and AMIOVIRT Investigators
Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemicdilated cardiomyopathy and asymptomaticnonsustained ventricular tachycardia--AMIOVIRT
J. Am. Coll. Cardiol., May 21, 2003; 41(10): 1707 - 1712.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. S. Lee, L. D. Green, P. P. Liu, P. Dorian, D. M. Newman, F. C. Grant, J. V. Tu, and D. A. Alter
Effectiveness of implantable defibrillators for preventing arrhythmic events and death: A Meta-Analysis
J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1573 - 1582.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
P. Della Bella, R. De Ponti, J.A.S. Uriarte, C. Tondo, C. Klersy, C. Carbucicchio, C. Storti, S. Riva, and M. Longobardi
Catheter ablation and antiarrhythmic drugs for haemodynamically tolerated post-infarction ventricular tachycardia. Long-term outcome in relation to acute electrophysiological findings
Eur. Heart J., March 1, 2002; 23(5): 414 - 424.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. J. Bailey, A. S. Berson, H. Handelsman, and M. Hodges
Utility of current risk stratification tests for predicting major arrhythmic events after myocardial infarction
J. Am. Coll. Cardiol., December 1, 2001; 38(7): 1902 - 1911.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
G. D. Sanders, M. A. Hlatky, N. R. Every, K. M. McDonald, P. A. Heidenreich, L. S. Parsons, and D. K. Owens
Potential Cost-Effectiveness of Prophylactic Use of the Implantable Cardioverter Defibrillator or Amiodarone after Myocardial Infarction
Ann Intern Med, November 20, 2001; 135(10): 870 - 883.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
P Mazeika
Aborted sudden cardiac death: a clinical perspective
Postgrad. Med. J., June 1, 2001; 77(908): 363 - 370.
[Abstract] [Full Text]


Home page
J CARDIOVASC PHARMACOL THERHome page
A. J. Camm and Y. G. Yap
Clinical Trials of Antiarrhythmic Drugs in Postmyocardial Infarction and Congestive Heart Failure Patients
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2001; 6(1): 99 - 106.
[PDF]


Home page
EuropaceHome page
P. Dorian and D. Newman
Rate dependence of the effect of antiarrhythmic drugs delaying cardiac repolarization: an overview
Europace, January 1, 2000; 2(4): 277 - 285.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
M. H. Crawford, S. J. Bernstein, P. C. Deedwania, J. P. DiMarco, K. J. Ferrick, A. Garson Jr, L. A. Green, H. L. Greene, M. J. Silka, P. H. Stone, et al.
ACC/AHA guidelines for ambulatory electrocardiography: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography) developed in collaboration with the North American Society for Pacing and Electrophysiology
J. Am. Coll. Cardiol., September 1, 1999; 34(3): 912 - 948.
[Full Text] [PDF]